Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1075 of 1631 entries
View as:

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Phase: N/A Priority: Normal
NCT ID: NCT01976741 Org: User:
Start: 12/30/13 End: 01/09/20 Due: 01/09/21

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

Phase: N/A Priority: Normal
NCT ID: NCT02023697 Org: User:
Start: 03/10/14 End: 08/09/18 Due: 08/09/19

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid

Phase: N/A Priority: Normal
NCT ID: NCT03746275 Org: User:
Start: 11/13/18 End: 07/13/21 Due: 07/13/22

18349-Human Photoallergy Test

Phase: N/A Priority: Normal
NCT ID: NCT02823496 Org: User:
Start: 11/30/15 End: 11/30/15 Due: 11/30/16

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT02283762 Org: User:
Start: 01/15/15 End: 03/28/19 Due: 03/28/20

Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea

Phase: N/A Priority: Normal
NCT ID: NCT01892904 Org: User:
Start: 07/31/13 End: 08/31/15 Due: 08/31/16

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00299390 Org: User:
Start: 04/30/06 End: 04/30/07 Due: 04/30/08

A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions

Phase: N/A Priority: Normal
NCT ID: NCT05428397 Org: User:
Start: 06/30/22 End: 10/28/22 Due: 10/28/23

Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients

Phase: N/A Priority: Normal
NCT ID: NCT03349684 Org: User:
Start: 03/05/18 End: 08/21/19 Due: 08/21/20

A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe

Phase: N/A Priority: Normal
NCT ID: NCT04925180 Org: User:
Start: 10/18/21 End: 12/31/21 Due: 12/31/22

Pharmacokinetic Study Comparing Aspirin and Aspirin Granules

Phase: N/A Priority: Normal
NCT ID: NCT01072604 Org: User:
Start: 07/31/09 End: 08/31/09 Due: 08/31/10

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Phase: N/A Priority: Normal
NCT ID: NCT03206931 Org: User:
Start: - End: - Due: -

Androcur Effects on Quality of Life

Phase: N/A Priority: Normal
NCT ID: NCT00908674 Org: User:
Start: 06/30/08 End: 01/31/10 Due: 01/31/11

Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT01077076 Org: User:
Start: 12/31/08 End: 03/31/09 Due: 03/31/10

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00984282 Org: User:
Start: 10/15/09 End: 08/30/17 Due: 08/30/18

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

Phase: N/A Priority: Normal
NCT ID: NCT00567164 Org: User:
Start: 10/31/07 End: 11/30/09 Due: 11/30/10

18670 - Sun Protection Factor Assay

Phase: N/A Priority: Normal
NCT ID: NCT02801929 Org: User:
Start: 11/20/15 End: 11/30/15 Due: 11/30/16

Long-term Pre-dialysis Extension in Europe and Asia Pacific

Phase: N/A Priority: Normal
NCT ID: NCT02055482 Org: User:
Start: 06/24/14 End: 12/12/16 Due: 12/12/17

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT03644511 Org: User:
Start: 01/24/19 End: 09/30/19 Due: 09/30/20

A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT03901729 Org: User:
Start: 05/29/19 End: 05/21/21 Due: 05/21/22

Pilot Study to Assess Number of Patients for Main Trial

Phase: N/A Priority: Normal
NCT ID: NCT02734628 Org: User:
Start: 03/31/07 End: 04/30/07 Due: 04/30/08

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00111020 Org: User:
Start: 06/30/05 End: 10/31/08 Due: 10/31/09

Essure (Model ESS310) Placement Rate Study

Phase: N/A Priority: Normal
NCT ID: NCT02064413 Org: User:
Start: 03/17/14 End: 11/26/14 Due: 11/26/15

PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Phase: N/A Priority: Normal
NCT ID: NCT00867815 Org: User:
Start: 07/13/09 End: 03/28/18 Due: 03/28/19

Duration of Use of Highly Effective Reversible Contraception

Phase: N/A Priority: Normal
NCT ID: NCT02414919 Org: User:
Start: 04/01/15 End: 03/28/16 Due: 03/28/17